Lantheus (NASDAQ:LNTH) Trading Down 2.2% - Here's What Happened

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) shares fell 2.2% during trading on Friday . The stock traded as low as $89.62 and last traded at $89.96. 363,405 shares were traded during mid-day trading, a decline of 64% from the average session volume of 1,011,764 shares. The stock had previously closed at $91.94.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on LNTH shares. Truist Financial reaffirmed a "buy" rating and set a $120.00 price target (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. JMP Securities lowered their target price on Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a research report on Thursday, November 7th. Redburn Atlantic began coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price target for the company. StockNews.com cut shares of Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. Finally, The Goldman Sachs Group began coverage on Lantheus in a report on Wednesday. They set a "buy" rating and a $143.00 price target for the company. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $131.86.

Lantheus Trading Down 2.9 %

The stock's fifty day moving average is $96.63 and its two-hundred day moving average is $98.18. The firm has a market cap of $6.21 billion, a P/E ratio of 14.86 and a beta of 0.45.

Institutional Investors Weigh In On Lantheus

A number of institutional investors and hedge funds have recently made changes to their positions in LNTH. Wilmington Savings Fund Society FSB purchased a new stake in shares of Lantheus in the 3rd quarter valued at about $25,000. Signaturefd LLC increased its position in shares of Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock worth $35,000 after purchasing an additional 92 shares during the last quarter. Nkcfo LLC purchased a new stake in Lantheus in the second quarter valued at approximately $47,000. UMB Bank n.a. lifted its position in Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock valued at $47,000 after purchasing an additional 126 shares during the last quarter. Finally, Kathleen S. Wright Associates Inc. purchased a new position in Lantheus in the 3rd quarter worth approximately $51,000. Hedge funds and other institutional investors own 99.06% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.